30-Second Takeaway
- Opportunistic salpingectomy substantially lowers tubo-ovarian and serous cancer risk with minimal short-term downside.
- mNC-FET outcomes are similar regardless of luteal progesterone support or day-6 versus day-7 transfer.
- Population FMF-based aspirin programs may not reduce preterm preeclampsia in routine practice.
- Teleultrasound can safely extend antenatal imaging capacity when technology and indication selection are appropriate.
- Antenatal corticosteroids are frequently mistimed or unnecessary, highlighting prediction and stewardship gaps.
Week ending February 7, 2026
Opportunistic salpingectomy, hypertension prevention strategies, and optimizing perinatal interventions
ESGO consensus: opportunistic salpingectomy as routine tubo-ovarian cancer prevention
This ESGO consensus synthesized 129 of 230 identified studies on opportunistic salpingectomy during gynecologic and nongynecologic surgery. Across observational data, opportunistic salpingectomy is significantly associated with reduced subsequent tubo-ovarian carcinoma risk. Short-term data show little added operative time, no increase in surgical complications, and no measurable short-term harm to ovarian function. Long-term evidence on menopause timing and ovarian reserve is still limited, so counseling should acknowledge residual uncertainty. The panel recommends routinely discussing salpingectomy as a prevention option during benign pelvic or abdominal procedures.
Late-pregnancy vaginal microbiota linked to balloon induction outcomes
This multicenter cohort followed 635 women undergoing planned balloon plus oxytocin induction, collecting pre-induction vaginal and cervical samples. Metagenomic profiling identified distinct vaginal microbiota patterns associated with delivery within 24 hours, later delivery, induction failure, or cesarean. Genome-wide association and rat microbiota transplantation studies support a biologically plausible influence of vaginal microbiota on cervical ripening and labor. The results suggest potential for microbiome-informed prediction of induction success but are not ready for clinical application or protocol changes.
mNC-FET: no clear benefit from luteal progesterone or earlier blastocyst transfer
This multicenter randomized trial allocated 602 women undergoing modified natural-cycle FET to four groups varying progesterone luteal support and transfer day. Live birth rates were similar with and without progesterone support, around one-third in each group (adjusted risk difference 3.18; 95% CI -4.13 to 10.49). Day-6 versus day-7 blastocyst transfer after hCG trigger produced nearly identical live birth rates (adjusted risk difference -0.62; 95% CI -7.99 to 6.75). Most participants were young and lean, and the study may be underpowered for small effects, but findings support omitting routine luteal progesterone in mNC-FET.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.